One site promises rock-bottom prices, another tacks on a membership fee you only notice at checkout, and a third raises your monthly bill the moment your dose goes up
Randomized trials (direct AD studies) Liraglutide (ELAD Phase 2b): In people with mild AD, 12 months of liraglutide slowed brain atrophy (MRI) and was associated with an ~18% slower cognitive decline versus placeboencouraging but still preliminary and not yet a practice-changing Phase 3 outcome
For beta-blocker initiation, there were no significant differences observed."Seeing these patterns of lower use of emergency care and lower use of drugs to stop migraines or trying additional drugs to prevent migraines among people taking GLP-1 drugs for other conditions suggests that these therapies may help stabilize the disease burden in ways that we havent fully appreciated yet," Acar said in a statement.Press ReleaseMore Information.Sign up for our weekly HealthDay newsletter
Developing oral GLP-1 agonists would improve convenience, acceptance and adherence, potentially leading to better treatment outcomes, she said
There are still situations where people shouldnt take certain weight-management medications